Patients with specific skin disorders who are affected by COVID-19: What do experiences say about management strategies? A systematic review

Niloufar Najar Nobari | Azadeh Goodarzi

Department of Dermatology, Rasoul Akram Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran

Correspondence
Azadeh Goodarzi, Department of Dermatology, Rasoul Akram Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Email: azadeh_goodarzi1984@yahoo.com, goodarzi.a@iums.ac.ir

Abstract
In patients with specific dermatologic disorders who are affected by new coronavirus, we know little about disease course (underlying disease and new onset infection), and the most proper management strategies include both issues that are what this systematic review targets. Databases of PubMed, Scopus, Google Scholar, Medscape, and Centre of Evidence-Based Dermatology, coronavirus dermatology resource of Nottingham University searched completely up to May 15, 2020, and initial 237 articles were selected to further review and finally 9 articles (including 12 patients) entered to this study. From 12 patients with chronic underlying dermatologic disease treated with systemic therapies, only 1 patient required Intensive Care Unit admission, the others have been treated for mild-moderate symptoms with conventional therapies. The biologic or immunosuppressive/immunomodulator agents have been ceased during the course of disease. The course of coronavirus diseases 2019 (COVID-19) and its management was as similar as normal populations. Their underlying dermatologic disease were exacerbating from mild to moderate. Their treatment has been continued as before, after the symptoms improved. Exacerbation of patients underlying dermatologic disease was mild to moderate. Discontinuing the treatment in the acute period of COVID and the restart after recovery may prevent severe recurrence and disturbing cytokine storms in these patients.

KEYWORDS
biologic, concomitant, concurrent, coronavirus, COVID-19, cutaneous, immunobullous, immunomodulator, immunosuppressive, manifestation, novel human coronavirus (SARS-CoV-2), pemphigoid, pemphigus, psoriasis, psoriatic arthritis, simultaneous, skin, specific skin disease, systematic review, systemic drug

1 | INTRODUCTION

Considering new coronavirus pandemic, medical approaches affect significantly by many aspects including new encountered virus-associated primary or secondary outcomes like various clinical conditions and their related managements, so that dermatology is not an exception. Recently, there are many published coronavirus diseases 2019 (COVID-19) and related dermatology articles, so that many data resources centers like coronavirus dermatology resource of Nottingham University (Centre of Evidence-Based Dermatology [CEBD]) categorize articles into some main domains as skin manifestations of coronavirus, Implications of coronavirus for use of biologics and other immune-modulating

Abbreviations: BMI, body mass index; CEBD, Centre of Evidence-Based Dermatology; COVID-19, coronavirus diseases 2019; CsA, cyclosporine; IL-23, interleukin-23; IVIg, intravenous immunoglobulins; MPM, mycophenolate mofetil; MTX, methotrexate; RTX, rituximab; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
therapies, Occupational skin disease, including effects of gloves, personal protective equipment and handwashing on the skin, coronavirus and specific patient groups, dermatology service delivery during the coronavirus epidemic, teledermatology, hydroxychloroquine, chloroquine, antibiotics and antivirals, coronavirus etiology, severity and transmission, dermatologic guidelines on coronavirus or relevant for coronavirus.

It is documented that there are specific skin and mucosal primary presentations of COVID-19 that could proceed or concomitantly accompany other clinical signs of disorder with diagnostic or prognostic values in approaching the patients.1-10 Exanthematous (molliform) or maculopapular eruptions,12-16 generalized urticaria17,18 and “COVID toes” (an acral vasculopathic rash also known as pseudo-chilblain or Pernio-like lesions),19-22 acral and digital ischemia,23-26 petechial27-29 and vesicular chicken-pox like lesions,30,31 levidoreticularis,32 and conjunctivitis3 are among the most reported virus-related dermatologic manifestations. There are growing reports of dermatologic manifestation among children like molliform or urticarial rash and conjunctivitis33,34 or nonspecific exanthematous, urticarial rashes, and facial ulceration in affected infants may born from infected mothers.33,35 Hydroxychloroquine-induced rashes solely or in combination with other therapies, are responsible for the main cutaneous drug reactions especially generalized pustular eruptions.36-38

There are some secondary COVID-19-related dermatoses like incidence of an acute new dermatologic entity for a limited time period that could be stress related (eg, herpes simplex, herpes zoster, alopecia areata, ...) or physical-environmental related (eg, contact dermatitis, acute urticaria, ...) or presence of a new dermatoses which have tendency to become chronic, like telogen-effluvium, various types of dermatitis, neurocutaneous, or psychocutaneous disorders. In the pandemic, some preexisting chronic dermatoses may become poorly controlled or aggravated by the stress, irregular visits, treatment interruptions, delayed therapies, physical and environmental situations like wearing masks and latex gloves, frequent washing and disinfectants, excessive sweating, and so on.11 Dermatologic visits and cosmetic or elective surgical procedure have been affected largely by a decreasing manner during pandemic.39 Adherence to personal and social hygiene strategies, social isolation, and distance are the rules of pandemic for better controlling any situations and the role of teledermatology is really important in this area regarding educational and therapeutic issues.40

In dermatology, one of the most important concerns in the pandemic setting is the manner of disease management especially in the case of patients under treatment with immunosuppressive immunomodulators. Noninfected non-at-risk patients do not need to any change in their therapeutic protocols but at-risk patients or who suspected to being infected (like having suggestive symptoms) need altering drug regimen as dose reduction, increase dose interval or transient stop of drug usage for at least 2 weeks. It is not any doubt that, every patient with an active corona virus infection should discontinue systemic biologic or nonbiologic immunosuppressive for at least 1 month or completely being symptom free. A more severe COVID-19 course is usually predictable in the setting of dermatologic diseases which are treating by systemic immunomodulators. Presence of any comorbidities related to underlying dermatologic disorder (like older age, metabolic syndrome and vital organ dysfunctions especially respiratory and cardiovascular involvements that may be seen in psoriatic or atopic patients or who with hidradenitis suppurativa, immunobullous, or collagen vascular disorders) is associated with poorer outcomes in the case of being infected by COVID-19. Some studies suggested that more sever skin conditions are at risk for higher rate of pneumonia and symptomatic respiratory involvement. In future, vaccination of these groups of patients is one of priority issues. It seems that in patients with any severe and serious dermatologic disorders, under treatment with systemic agents, if there is not any suspicion about concurrent infection or any high risk exposures, not only it is not recommend to cessation therapy but only emphasize that these drugs could prevent disease flare-up and control cytokine storm that both in a negative direction, affect the COVID-19 course.41-48

One of the most important perspectives in the field of dermatology is approaching to patients with any documented skin or mucosal disorders especially who are using immunomodulators and now are affected by COVID-19. For consensus and more exact expert recommendations in this group of patients, we need data gathering about people who were in this situation and know more about what experiences say about dermatologic disease course, COVID-19 course and the manner of managing both conditions in the best possible way? So in this systematic review we focused on specific patient groups with a dermatologic disorder (usually under therapy) that concomitantly have been infected by the new corona virus and summed up their data in all aspects of underlying dermatologic and infectious disease courses and managements.

2 | METHOD

2.1 | Protocol and registration

This study is implemented according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.

2.2 | Eligibility criteria

Inclusion criteria comprised all studies about patients with any documented skin or mucosal disorders especially who were using immunomodulators and now were affected by COVID-19. The exclusion criteria consisted of all publications not meeting the above contents and non-English literature.

2.3 | Information sources and search strategy

We searched Databases of PubMed, Scopus, Google Scholar, Medscape, and CEBD coronavirus dermatology resource of Nottingham University (https://www.nottingham.ac.uk/). Our key words were “COVID-19" OR...
| First author | Title                                                                 | Type of study | Case characteristic | Patients underlying dermatologic disease | Patients comorbidity | Drug history | COVID-19 sign and symptoms | COVID-19 courses | Managements of disease |
|--------------|-----------------------------------------------------------------------|---------------|---------------------|------------------------------------------|----------------------|--------------|----------------------------|----------------|------------------------|
| A. Conti     | Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs | Case report   | Case 1: A 62-y-old man | Psoriasis                               | Hypertension, diabetes, chronic renal failure, and overweight (BMI: 29) | Guselkumab    | ARDS                       | 1 mo of hospitalization with 2 wk Intensive Care Unit admission | Almost complete resolution of respiratory symptoms; despite discontinuation of guselkumab, psoriasis remained in complete remission |
|              |                                                                       |               | Case 2: A 66-y-old man | Psoriasis                               | Hypertension, dyslipidemia, and previous myocardial infarction | Ustekinumab  | Asthenia, anosmia, and ageusia | He achieved complete remission of symptoms without any medications after a month | Maintenance of the remission of psoriasis |
|              |                                                                       |               | Case 3: A 67-y-old woman | Psoriasis                               | Hypertension and metabolic syndrome | Adalimumab  |                          |                              |                        |
|              |                                                                       |               | Case 4: A 66-y-old man | Psoriasis                               | Hypertension, diabetes, metabolic syndrome, and obesity (BMI: 32) | Secukinumab  |                          |                              |                        |
| R. Balestri  | Occurrence of SARS-CoV-2 during mycophenolate mofetil (MPM) treatment for pemphigus | Case report   | A 65-y-old female | Pemphigus                                | Not reported         | MPM          | Severe nausea, fever, anorexia, and asthenia | She had her symptoms for 12 days and the treatment was only symptomatic with paracetamol. From the first her symptoms, the MPM has been discontinued | The patient did not experience any pemphigus recurrence, but reported only some posterior tongue “discomfort.” Moreover, she never developed cough, dyspnea, anosmia, ageusia, myalgia or other symptoms of the infection |
| M. Daneshpazhooh | Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case-report | Case report   | A 43-y-old man | Mucous membrane pemphigoid (MMP) | Diabetes, hypertension and benign prostatic hypertrophy | Prednisolone Rituaximab (RTX) MPM/high-dose intravenous immunoglobulins (IVIg) | Fever, chills, malaise, dry cough and mild dyspnea | Upon admission, MMF was discontinued, prednisolone was tapered, and IVIg was started. The patient received hydroxychloroquine, oseltamivir, lopinavir/ritonavir, antibiotics | The patient was discharged on day 7 with significant improvement. His lymphopenia also recovered completely. He was followed for 2 wk |

(Continues)
| First author | Title                                                                 | Type of study | Case characteristic | Patients underlying dermatologic disease | Patients comorbidity | Drug history | COVID-19 sign and symptoms | COVID-19 courses | Managements of disease |
|--------------|-----------------------------------------------------------------------|---------------|---------------------|------------------------------------------|----------------------|--------------|---------------------------|-----------------|------------------------|
| C. Mugheddu | COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management | Case report   | A 45-y-old man      | Psoriasis/brain oligodendroglioma         | Obesity, recent chemotherapy, persistence of brain oligodendroglioma | Chemotherapy with temozolomide/prednisone/apremilast | Severe cough with high fever | Lopinavir/ritonavir, ceftriaxone | The infection recovered rapidly and the patient was discharged 6 d after the onset of symptoms. Apremilast had never been stopped during the COVID-19 hospitalization, with acceptable control of the psoriasis, limited to mild scaling and erythema, especially on the trunk |
| S. Nasiri   | A challenging case of psoriasis flare-up after COVID-19 infection     | Case report   | A 73-y-old male     | Psoriasis                                | Not reported         | Methotrexate cyclosporine (CsA) | Fever, malaise, dry cough | CsA and MTX were ceased. The patient was treated with hydroxychloroquine, lopinavir/ritonavir | His symptoms resolved in 2 wk but he returned with flare-up of his underlying psoriasis manifesting as diffuse erythematous scaly plaques progressing to erythroderma. Two weeks after the improvement of COVID-19 symptoms, psoriasis treatment with CsA 100 mg daily was restarted |
| V. Di Lerni | COVID-19 in an elderly patient treated with secukinumab               | Case report   | A 73-y-old woman    | Psoriasis/psoriatic arthritis            | Not reported         | Secukinumab | Fever, sore throat, mild dry cough | Hydroxychloroquine | The symptoms were relieved after about a week. The injection of secukinumab was continued during disease |
| Ö. Kutlu    | A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic | Case report   | A 71-y-old woman    | Psoriasis                                | Not reported         | Not reported | Not reported | The patient has been managed by oseltamivir and hydroxychloroquine | Not reported |
Severe Acute Respiratory Syndrome Coronavirus 2 AND "Skin" OR "Skin Diseases" OR "Skin Manifestations" OR "Dermatology" OR "Skin and Connective Tissue Diseases" OR "Eczematous" OR "Eczema" OR "Eczematous Dermatitis" OR "Eczematous Eruption" OR "Eczematous Skin" OR "Dermatitis, Atopic" OR "Papulosquamous" OR "Psoriasis" OR "Hidradenitis, Suppurativa" OR "Alopecia" OR "Pemphigus" OR "Pemphigoid" OR "Immunobullous" OR "Skin Cancer" OR "Dermatologic Agents" OR "Immunomodulator" OR "Systemic Drugs" OR "Biologics" OR "Immunomodulator" OR "Immunospress" OR "Immunospressive." In the search of CEBD coronavirus dermatology resource of Nottingham University we focused on the link of skin manifestations of coronavirus and specific patient groups. We finally complete our search up to May 15, 2020.

2.4 Study selection

In the first screening 237 articles assigned to the inclusion and exclusion groups and then the titles and abstracts of articles were reviewed by 2 expert dermatologists and acceptable articles searched to find their full text and finally 9 articles (including 12 patients) selected to data entry for this systematic review.

3 RESULTS

After researching, we have found nine related articles and the information of these articles are prepared as a table. Of the 12 patients reviewed in these articles, 10 had psoriasis/psoriatic arthritis and 2 had immunobullous disease included pemphigus and mucous membrane pemphigoid. Their underlying disease was treated with the following drugs:

- From patients with psoriasis/psoriatic arthritis, eight patients were treated with biologic agents (guselkumab: three patients, secukinumab: two patients, apremilast: one patient, adalimumab: one patient, ustekinumab: one patient); two patients were on other immunosuppressive/immunomodulators agents include cyclosporine (CsA) and methotrexate.
- One patient with mucous membrane pemphigoid was treated with prednisolone, rituximab (RTX), mycophenolate mofetil (MPM), and high-dose intravenous immunoglobulins (IVIg).
- One patient with pemphigus was treated with MPM.

In Table 1, we summerized all data about concomitant presence of dermatologic diseases and COVID-19.

4 DISCUSSION

At the time of the pandemic, many patients were diagnosed with various dermatoses treated with biological agents or immunosuppressive/ immunomodulators. Although, there is still no strong evidence
of a higher risk of infection with COVID-19 in these patients, and clinicians emphasizes that the symptoms and management of disease in these patients are similar to those in the general population. In addition, for many dermatoses like other medical problems, any mental or physical stress, such as anxiety or infection, may exacerbate the disease course. This study has evaluated nine case reports of patients with chronic dermatologic diseases treated with systemic agents. Of the 12 patients reported, the two patients did not show any symptoms despite close contact with people with confirmed cases of COVID-19; at the time of quarantine, these patients showed no signs of the disease and their treatment continued as before. Of the remaining 10 patients, only one required hospitalization in the intensive care unit. Five patients were treated with conventional therapies such as hydroxychloroquine, oseltamivir, lopinavir/ritonavir, antibiotics. Other patients were treated with supportive/symptomatic therapies. At the time of the COVID-19, the biologic agents were discontinued except for one case (which was treated with guselkumab) but the patients did not report any severe exacerbation of their underlying dermatologic disease despite treatment discontinuation. There was only one case of severe relapse of psoriasis after COVID-19, in which the patient was previously treated with CsA and methotrexate.

Investigation of these articles showed that the severity of COVID-19 in patients with underlying dermatologic disease treated with biological agents was not more than in the general population. The management of these patients was in the form of discontinuation of the biological agents or immunosuppressive/immunomodulators and the use of routine and conventional treatments. After the symptoms have improved, treatment of the underlying dermatologic disease can be recommenced as before.

5 | CONCLUSIONS

Our knowledge about managing patients with dermatologic disorders (especially chronic disorders under treatment with systemic immunomodulators) who are affected by COVID-19 in the pandemic is really scarce given this issue for better controlling and managing both underlying dermatoses and concurrent coronavirus infections, we need to sum up current relevant data that we did in this systematic review so far. We found that the severity of the disease or the need for hospitalization in these patients was not greater than in normal population. The treatment of the disease in confirmed cases with COVID-19 were similar to that of affected normal population, with the difference that it is better to stop the patient’s previous medications until the symptoms improve. In patients who have already been treated with biological drugs, recurrence or exacerbation of underlying dermatologic disease was mild. After the symptoms of the disease have improved, the patient’s treatment could be continued as before.

ACKNOWLEDGMENT

The authors would like to thank Rasoul Akram Hospital Clinical Research Development Center (RCRDC) for its technical and editorial assists.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

The authors contribute equally to all stages of this study. The team has reviewed the manuscript and the data, and all contributors were in full agreement.

ORCID

Niloufar Najar Nobari https://orcid.org/0000-0002-4245-1980
Azadeh Goodarzi https://orcid.org/0000-0002-1249-4429

REFERENCES

1. Galvan Casas C, Catala A, Carretero Hernandez G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19163.
2. Estébanez A, Pérez-Santiago L, Silva E, Guilen-Climent S, Garcia-Vázquez A, Ramón MD. Cutaneous manifestations in COVID-19: a new contribution. J Eur Acad Dermatol Venereol. 2020;34. https://doi.org/10.1111/jdv.16474.
3. Ahouach B, Harant S, Ullmer A, et al. Cutaneous lesions in a patient with COVID-19: are they related? Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19168.
4. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34:e210-e240.
5. Hedou M, Carsuzaa F, Chary E, Hainaut E, Cazenave-Roblot F, Masson RM. Comment on "Cutaneous manifestations in COVID-19: a first perspective" by Recalcati S. J Eur Acad Dermatol Venereol. 2020;34. https://doi.org/10.1111/jdv.16470.
6. Gianotti R, Zerbi P, Dodiuk-Gad RP. Clinical and histopathological study of skin dermatoses in patients affected by COVID-19 infection in the northern part of Italy. J Dermatol Sci. 2020;98:141-143. https://doi.org/10.1016/j.jdermsci.2020.04.007.
7. Sachdeva M, Gianotti R, Shah M, et al. Cutaneous manifestations of COVID-19: report of three cases and a review of literature. J Dermatol Sci. 2020;98:75-81. https://doi.org/10.1016/j.jdermsci.2020.04.011.
8. Rivera-Oyola R, Koschitzky M, Prinyi R, et al. Dermatologic findings in two patients with COVID-19: JAAD Case Rep. 2020;6(6):537-539.
9. Avellana Moreno R, Villa E, Avellana Moreno V, Estela Villa C, Aparicio M, Fontanella A. Cutaneous manifestation of COVID-19 in images: a case report. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16531.
10. Lu S, Lin J, Zhang Z, et al. Alert for non-respiratory symptoms of coronavirus disease 2019 (COVID-19) patients in epidemic period: a case report of familial cluster with three asymptomatic COVID-19 patients. J Med Virol. 2020. https://doi.org/10.1002/jmv.25776.
11. Elston DM. Occupation skin disease among health care workers during the coronavirus (COVID-19) epidemic. J Am Acad Dermatol. 2020;82(5):1085-1086.
12. Mahé A, Birkel E, Krieger S, Merklen C, Bottlaender L. A distinctive skin rash associated with coronavirus disease 2019? J Eur Acad Dermatol Venereol. 2020;34. https://doi.org/10.1111/jdv.16471.
13. Hunt M, Koziatek C. A case of COVID-19 pneumonia in a young male with full body rash as a presenting symptom. Am J Emerg Med. 2020;42(2):219-221.
14. Najarian DJ. Morbilliform exanthem associated with COVID-19. JAAD Case Rep. 2020;6(6):493-494.
15. Hoenig LJ, Pereira FA. Rash as a clinical manifestation of COVID-19 photographs of a patient. Clin Dermatol. 2020. https://doi.org/10.1016/j.clindermatol.2020.04.001.
16. Amatore F, Macagno N, Mailhe M, et al. SARS-CoV-2 infection presenting as a febrile rash. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16528.

17. Henry D, Ackerman M, Sancelme E, Finon A, Esteve E. Urticarial eruption in COVID-19 infection. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16622.

18. Quintana-Castanedo L, Feito-Rodríguez M, Valero-López I, Chiloeches-Fernández C, Sendagorta-Cudós E, Herranz-Pinto P. Urticarial exanthem as early diagnostic clue for COVID-19 infection. JAAD Case Rep. 2020;6(6):499-499.

19. Landa N, Mendieta-Eckert M, Fonda-Pascual P, Aguirre T. Chilblain-like lesions on feet and hands during the COVID-19 pandemic. Int J Dermatol. 2020;59(6):739-743.

20. Jimenez-Cauhe J, Ortega-Quijano D, Prieto-Barrios M, Moreno-Arrones LM. Chilblain-like lesions during the COVID-19 pandemic. First report from the Middle East. Clin Exp Dermatol. 2020. https://doi.org/10.1111/ced.14243.

21. Alramthan A, Aldaraji W. A case of COVID-19 presenting in clinical picture resembling chilblains disease. First report from the Middle East. Clin Exp Dermatol. 2020. https://doi.org/10.1111/ced.14243.

22. Piccolo V, Neri I, Filippeschi C, et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16526.

23. Megro C, Mulvej JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;5:1931-5244(20):30070-0.

24. Recalcati S, Barbagallo T, Frasin LA, et al. Acral cutaneous lesions in COVID-19: a case series of 22 patients. J Am Acad Dermatol. 2020;82(5):e177.

25. Mazzotta F, Troccoli T. Acute acro-ischemia in the child at the time of COVID-19. Eur J Pediatr Dermatol. 2020.

26. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med. 2020;382(17):1803-1812.

27. Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for dengue. JAMA Dermatol. 2020;82(5):e177.

28. Recalcati S, Barbagallo T, Frasin LA, et al. Acral cutaneous lesions in the time of COVID-19. J Eur Acad Dermatol Venereol. 2020. https://doi.org/10.1111/jdv.16533.

29. Marzano AV, Genovese G, Fabbrocini G, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol. 2020;82(5):e177.

30. Marzano AV, Genovese G, Fabbrocini G, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol. 2020;82(5):e177.

31. Genovese G, Colonna C, Marzano AV. Varicella-like exanthem associated with COVID-19 in an 8-year-old girl: a diagnostic clue? Pediatr Dermatol. 2020. https://doi.org/10.1111/pde.14201.

32. Manalo IF, Smith MK, Cheeley J, Jacobs R. A dermatologic manifestation of COVID-19: transient livedo reticularis. J Am Acad Dermatol. 2020. https://doi.org/10.1016/j.jaad.2020.04.018.

33. Morey-Olive M, Espiau M, Mercadal-Hally M, Lera-Carbello E, Garcia-Patós V. Cutaneous manifestations in the current pandemic of coronavirus infection disease (COVID-19) 2019. An Pediatr. 2020. https://doi.org/10.1016/j.anpede.2020.04.002.

34. Wu P, Liang L, Chen C, Nie S. A child confirmed COVID-19 with only symptoms of conjunctivitis and eyelid dermatitis. Graefes Arch Clin Exp Ophthalmol. 2020;1-2.

35. Chen Y, Peng H, Wang L, et al. Infants born to mothers with a new coronavirus (COVID-19). Front Pediatr. 2020;8:104.

36. Sharma AN, Mesinkovska NA, Paravar T. Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review. J Am Acad Dermatol. 2020;82(5):e177.
Pandemic emergency: a quick review for a quick consultation. Dermatol Ther. 2020;e13537.

58. Gupta MA, Gupta AK. Evaluating the Role of Stress in Skin Disease. Stress and Skin Disorders. Cham: Springer; 2017:11-17.

59. Alsamarai AM, Aljubori AM. Association between stress and skin disease. MEJIM. 2010;3:12-19.

60. Keeling E, Daly S, DB MK. Dermatology patients’ knowledge and concerns regarding their immunomodulatory medication during the COVID-19 pandemic. Dermatol Ther. 2020;e13488.

How to cite this article: Nobari NN, Goodarzi A. Patients with specific skin disorders who are affected by COVID-19: What do experiences say about management strategies? A systematic review. Dermatologic Therapy. 2020;33:e13867. https://doi.org/10.1111/dth.13867